FDA Nervous System Panel Dies Then Rises From Dead
Published Date: 7/23/2026
Notice
Summary
The FDA ended the Peripheral and Central Nervous System Drugs Advisory Committee on June 4, 2026, because its charter wasn’t renewed on time. But good news—the committee is back and officially reestablished starting July 30, 2026, for two more years to keep advising on brain and nerve drug safety. This means experts will continue helping the FDA make smart decisions about nervous system medicines without missing a beat.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14898, FDA's Strategy Document on Facilitating Chemistry, Manufacturing, and Controls Readiness for Products With Accelerated Clinical Development
The FDA is rolling out a new plan to speed up how drugs and biologics are made and tested, especially for serious diseases that need fast solutions. This affects drug makers who want to bring treatments to patients quicker by improving the chemistry, manufacturing, and controls process. Starting now through 2027, these changes aim to save time and help get important medicines to people faster without extra costs.
2026-14910, Revocation of the Color Additive Listing for Use of Orange B on Casings or Surfaces of Frankfurters and Sausages
The FDA is officially banning the use of the color additive Orange B on frankfurter and sausage casings because it’s no longer used or needed. This change affects food makers who color these meats and takes effect on September 8, 2026. If anyone disagrees, they have until August 24, 2026, to speak up—no extra costs or surprises, just a cleaner, clearer food color rule!
2026-14909, Proposal To Revoke the Color Additive Listing for Use of Citrus Red No. 2 on the Skins of Mature Oranges
The FDA wants to stop allowing Citrus Red No. 2 to be used on orange skins because it hasn’t been used since 2020. This change affects orange growers and food companies but won’t cost anyone money since the color additive is already out of use. If you have thoughts, you’ve got until August 24, 2026, to speak up!
2026-14779, Determination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that RASUVO (methotrexate) solution wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and possibly cheaper for patients who need this medicine. If all rules are met, these generics could hit the market soon, helping more people get access without breaking the bank.
Previous / Next Documents
Previous: 2026-14828, Certain Alkyl Phosphate Esters From the People's Republic of China: Initiation of Circumvention Inquiry on the Antidumping and Countervailing Duty Orders
The U.S. is checking if some alkyl phosphate esters from China are sneaking around existing trade rules. This could affect Chinese exporters and U.S. importers by possibly changing duties or taxes soon. The investigation aims to keep trade fair and protect American businesses from unfair pricing tricks.
Next: 2026-14830, Foreign-Trade Zone (FTZ) 210; Authorization of Limited Production Activity; P.J. Wallbank Springs, Inc.; (Spring Pack Assemblies Used in Automotive Transmissions); Port Huron, Michigan
P.J. Wallbank Springs, Inc. in Port Huron, Michigan, got the green light to do some limited production of spring pack assemblies used in car transmissions inside Foreign-Trade Zone 210. This means they can make parts with special customs benefits, helping them save money and speed up their work. The change kicks in right away, boosting local manufacturing and trade efficiency.